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Background: Oxidative stress (OS) and reduced nitric oxide (NO) bioavailability contribute to the pathogenesis of
pulmonary hypertension (PH). Whether there are associations between OS and NO signaling biomarkers and whether
these biomarkers are associated with the severity of PH remain unclear.
Methods: Blood samples were collected from 35 healthy controls and 35 patients with pulmonary arterial
hypertension (PAH, n = 12) or chronic thromboembolic pulmonary hypertension (CTEPH, n = 23). The mean pulmonary
artery pressure (mPAP) and pulmonary vascular resistance index (PVRI) were measured by right heart catheterization.
We measured the derivative of reactive oxygen molecules (d-ROMs), biological antioxidant potential (BAP) and
superoxide dismutase (SOD) by automatic biochemical analyzer, malondialdehyde (MDA) and asymmetric
dimethylarginine (ADMA) by enzyme-linked immunosorbent assay. The relationship between oxidative-antioxidative
biomarkers and ADMA, as well as their association with pulmonary hemodynamics, were analyzed.
Results: Compared with age- and gender-matched controls, there was no significant difference of d-ROMs in PAH
and CTEPH patients; MDA was increased in CTEPH patients (P = 0.034); BAP and SOD were decreased in PAH (P = 0.014,
P < 0.001) and CTEPH patients (P = 0.015, P < 0.001); ADMA level was significantly higher in PAH (P = 0.007) and CTEPH
patients (P < 0.001). No association between oxidative-antioxidative biomarkers and ADMA was found. Serum ADMA
concentration was correlated with mPAP (r = 0.762, P = 0.006) and PVRI (r = 0.603, P = 0.038) in PAH patients.
Conclusions: The antioxidative potential and NO signaling are impaired in PAH and CTEPH. Increased serum ADMA
level is associated with unfavorable pulmonary hemodynamics in PAH patients. Thus, ADMA may be useful in the
severity evaluation and risk stratification of PAH.
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Pulmonary hypertension (PH) is a complex pulmonary
vascular disease caused by different reasons, such as
chronic hypoxia, left heart diseases, chronic respiratory
diseases and thromboembolism [1]. In the classification
of PH by World Health Organization (WHO), pulmonary
arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) share the pathological* Correspondence: cyh-birm@263.net
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creativecommons.org/publicdomain/zero/1.0/characteristic of vascular remodeling. Pulmonary vascular
remodeling is characterized by medial hypertrophy,
intimal proliferative and fibrotic changes, adventitial
thickening, and thrombotic lesions [1]. Although the
mechanisms involved are incompletely understood,
endothelial dysfunction with proliferation of endothelial
cells and smooth muscle cells plays an important role in
vascular remodeling [2]. One character of endothelial
dysfunction is oxidative stress (OS) [3,4], which can
increase the production of reactive oxygen species (ROS)
and reactive nitrogen species (RNS) and decrease the
bioavailable nitric oxide (NO).ticle distributed under the terms of the Creative Commons Attribution License
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muscle cells, and adventitial cells, can produce ROS. In
patients with vascular diseases, the oxidative-antioxidative
balance in the vessel wall is compromised due to the
increase of ROS production by these cells, sometimes
coupled with decreased antioxidant defense. ROS may
trigger signals that further exacerbate smooth muscle
hypercontractility, endothelial barrier dysfunction, and
vascular remodeling [5], Increasing evidence demonstrates
that OS plays a contributory role in the pathogenesis of
PAH [6-9]. Recently, increased markers of OS have been
found in various animal models, such as C57/BL6
mice exposed to hypobaric hypoxic conditions and
Sprague-Dawley rats with monocrotaline-induced PAH
[10,11]. However, few studies have explored the roles of
oxidative-antioxidative biomarkers in PH patients.
NO is synthesized in the endothelium from L-arginine
by NO synthase. Asymmetric dimethylarginine (ADMA)
is an endogenous NO synthase inhibitor, which has been
implicated in the pathogenesis of various cardiovascular
diseases [12-16]. ADMA plasma levels are significantly
elevated in idiopathic pulmonary arterial hypertension
(IPAH), and correlated significantly with mixed-venous
oxygen saturation, right atrial pressure, cardiac index, as
well as survival [17,18].
Whether oxidative-antioxidative biomarkers and ADMA
are associated with mean pulmonary artery pressure
(mPAP) and pulmonary vascular resistance index (PVRI)
remains unclear. Both oxidative-antioxidative imbalance
and impaired NO signaling are involved in endothelial dys-
function and vascular remodeling. NO relaxes smooth
muscle and decreases its metabolism, which will reduce the
production of ROS. Thus, there may be some association
between ADMA and oxidative-antioxidative biomarkers,
which need to be investigated to further understand the
pathogenesis and pathophysiologic processes of PH.
Therefore, we designed this case-control study to meas-
ure the oxidative-antioxidative biomarkers and ADMA
level in the healthy controls, PAH patients, and CTEPH
patients, with an attempt to identify the association
between oxidative-antioxidative biomarkers and ADMA,
simultaneously evaluate the association between these
biomarkers and PH severity assessed by pulmonary
hemodynamics. The level of these biomarkers was
compared between PAH patients and their age- and
gender-matched controls, between CTEPH patients
and their age- and gender-matched controls respectively.
The oxidative biomarkers we assessed included derivative
of reactive oxygen molecules (d-ROMs) and malondialde-
hyde (MDA). Biological antioxidant potential (BAP) and
superoxide dismutase (SOD) were assessed as the antioxi-
dative biomarkers. d-ROMs and BAP, which are general
evaluation of oxidative and antioxidative status respect-
ively, have been used in the evaluation of disease severityand therapeutic effect in chronic obstructive pulmonary
disease [19], idiopathic pulmonary fibrosis [20] and other
diseases. ROS degrade polyunsaturated lipids, forming
MDA, which is used as a biomarker to measure the level
of OS in an organism [21,22]. SOD out-competes
damaging reactions of superoxide, protects the cell from
superoxide toxicity, and is widely used in scientific
research and clinical practice [23,24].
Methods
Study population
Consecutive adult patients newly diagnosed with PAH
or CTEPH by pulmonary angiography and right heart
catheterization were enrolled. PH has been defined as an
increase in mPAP ≥ 25 mmHg [25]. PAH is characterized
by the presence of pre-capillary PH, i.e., mPAP ≥25 mmHg,
pulmonary artery wedge pressure ≤15 mm Hg, and
elevated pulmonary vascular resistance >3 Wood units, in
the absence of other causes of pre-capillary PH. The final
diagnosis of CTEPH was based on the presence of pre-
capillary PH in patients with multiple chronic/organized
occlusive thrombi/emboli in the elastic pulmonary arteries.
Patients were excluded if they had unstable atherosclerotic
vascular disease, renal dysfunction, or untreated hyper-
lipidemia or if they were under treatment with nitrates,
NO donors, prostaglandins, endothelin receptor antago-
nists, sildenafil, or antioxidant therapy. The demographic
and clinical information, six minute walk distance
(6MWD) and WHO functional class of all the patients
was recorded. mPAP and PVRI were measured by right
heart catheterization.
Age- and gender-matched healthy candidates were
included as the control group for PAH group and
CTEPH group, respectively. Healthy controls were selected
from volunteers without any abnormality in the physical
examination and laboratory tests. The exclusion criteria
included: 1) with a history of respiratory disease, cardiac
disease, cardiovascular and cerebrovascular disease, chronic
liver and kidney failure, malignancy, diabetes mellitus,
and/or any additional medical disorders; 2) smoking;
and 3) using antioxidant drugs.
The study protocol was approved by the Ethics Committee
of Beijing Hospital (2014BJYYEC-051-01). Informed con-
sent was obtained from each subject.
Blood samples
Once the diagnosis was established, fresh blood samples
were collected before the treatment except the basic
treatment began. The basic treatment included diuretics,
oxygen, cardiotonics and other supportive treatment. We
used the separation gel coagulation promoting vacuum
tubes. Within 1 hour after sample collection, the blood
sample was centrifuged by 2280 g for 5 minutes. Then the
serum was stored at -80°C. All the serum samples were
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biomarkers, serum samples were balanced to room
temperature. Thawing and refreezing were avoided.
Measurement of d-ROMs
We measured d-ROMs level using the automatic bio-
chemical analyzer (HITACHI 7600 Series, Japan). The
method is based on the principle that in Tris-HCl
buffer (pH = 5), iron ions previously bonded to serum
proteins can release and catalyze the conversion of
serum hydroperoxides to alkoxyl and peroxyl radicals,
which further react with chromogen, dimethyl para-
phenylene diamine hydrochloride. Upon oxidation, its
color becomes lighter, which is measured at 505 nm. Tert
butyl hydroperoxide (TBHP) was used as standard
substance. The results were expressed as an equivalent of
mmol TBHP Equiv/L.
Measurement of BAP
BAP level was measured using the automatic biochemical
analyzer (AU 5400, Olympus, Japan). The assay is based
on the ability of a colored ferric thiocyanate to decrease in
absorption when Fe3+ ions are reduced to Fe2+. The
absorbance is measured photometrically at 520 nm and
calculating the amount of reduced ferric ions. Vitamin C
(VitC) was used as standard substance. The results were
expressed as an equivalent of mmol VitC Equiv/L.
Measurement of SOD, MDA and ADMA
SOD level was measured using the automatic biochemical
analyzer (AU 5400, Olympus, Japan) and a commercial kit
(Fujian Luck Bioscience CO. LTD, China).
MDA and ADMA levels were measured by the method
of enzyme-linked immunosorbent assay. Commercial
kits (KYM, China) were used. The standard substanceTable 1 Characteristics of patients with PAH or CTEPH and he
Variables PAH group (n = 12) PAH-Control (n = 12)
Male, n (%) 2 (16.7) 2 (16.7)
Age, years 44.6 ± 13.1 44.8 ± 13.2
BMI, kg/m2 25.66 ± 4.27 25.12 ± 3.73
Hypertension, n (%) 2 (16.7) -
Diabetes Mellitus, n (%) 0 (0) -
6MWD, m 253.50 (148.50, 368.25) -
NT-proBNP, pg/ml 1130.0 (373.9, 2312.0) -
mPAP, mmHg 50 (37, 55) -
PVRI, dyn · sec · m2/cm5 1398.0 (1149.0, 2647.5) -
CO, L/min 3.95 ± 1.21 -
CI, L/min/m2 2.27 ± 0.67 -
Data are presented as mean ± SD or median (interquartile range). PAH = pulmonary
hypertension; BMI = body mass index; WHO =World Health Organization; 6MWD = 6
mPAP =mean pulmonary arterial pressure; PVRI = pulmonary vascular resistance indand serum samples were incubated with MDA/ADMA
antibody. Subsequently, the peroxidase-conjugated
anti-human IgG was bound to the anti-MDA/ADMA
antibodies. After coloration for 15 min, the absorb-
ance of each well was measured at 450 nm with an
ultramark microplate reader (Bio-Rad, Hercules, CA).
The concentration for each sample was calculated
according to the standard curve, after subtraction of
the blank values.
Statistical analysis
SPSS software version 17.0 (Statistical Package for the
Social Sciences Inc., Chicago, IL, USA) was used to
analyze all the data. Kolmogorov-Smirnov method was
used to test whether the data was normal distributed.
Variables were presented as mean ± standard deviation,
median with quartiles, or constituent ratio as appropriate.
We used t test for two independent samples or nonpara-
metric test to compare the continuous variable and χ2
test to compare the categorical variable between groups.
Pearson Correlation was used to analyze the correlation
between variables. A P value < 0.05 was regarded as
statistically significant.
Results
Characteristics of study population
Totally 35 patients with PH and 35 healthy controls
were enrolled. Demographic data of the patients and
healthy controls were presented in Table 1. Among the
PH patients, 12 patients were diagnosed with PAH
(7 with idiopathic PAH, 4 with connective tissue diseases
associated PAH, 1 with familial PAH), and 23 were diag-
nosed with CTEPH. The mean age was 44.6 years in PAH
group and 55.0 years in CTEPH group. In PAH group, 2
patients (16.7%) were male. In CTEPH group, 12 patientsalthy controls
P value CTEPH group (n = 23) CTEPH-Control (n = 23) P value
1.000 12 (52.2) 11 (47.8) 0.768
0.963 55.0 ± 11.6 55.7 ± 11.5 0.839
0.894 25.75 ± 3.23 24.53 ± 3.01 0.748
- 5 (21.7) - -
- 1 (4.3) - -
- 275.00 (150.00, 419.00) - -
- 1723.0 (609.0, 3136.0) - -
- 52 (49, 55) - -
- 2231.5 (1595.75, 2611.5) - -
- 3.45 ± 1.19 - -
- 1.82 ± 0.52 - -
arterial hypertension; CTEPH = chronic thromboembolic pulmonary
-minute walk distance; NT-proBNP = N-terminal pro brain natriuretic peptide;
ex; CO = cardiac output; CI = cardiac index.
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and CTEPH groups were WHO functional class II-III
(74.9% and 87.0%, respectively). The comorbidity, 6MWD,
level of NT-proBNP and main parameters of pulmonary
haemodynamics were also presented in Table 1. The
median 6MWD was 253.50 m in PAH group and 275.00 m
in CTEPH group, respectively.
Comparison between PAH patients and PAH-controls
We compared the demographic characteristics and
biomarkers level between PAH patients and PAH-controls
(Table 1, Figure 1). The gender, age composition and BMI
were well-matched. The mean levels of BAP and SOD
were significantly lower in the PAH group compared withFigure 1 The comparison of oxidant-antioxidant biomarkers and ADMA lev
and D, presented as median (interquartile range) in Figure B. A. There was
and PAH-control group, or between CTEPH and CTEPH-control group. B. Th
their control group. The difference was only significant between CTEPH gro
BAP was significantly lower in patients with PAH or CTEPH. D. Compared w
PAH or CTEPH. E. Compared with controls, the level of ADMA was significathe control group (P = 0.014, P < 0.001, Figure 1C and D).
Patients in PAH group had significantly higher ADMA
level than the control group (P = 0.007, Figure 1E).
Comparison between CTEPH patients and CTEPH-controls
The demographic characteristics and biomarker levels
were also compared between CTEPH patients and
CTEPH-controls (Table 1, Figure 1). The mean level of
MDA was significantly higher in CTEPH group (P = 0.034,
Figure 1B). The levels of BAP and SOD were obviously
lower in the CTEPH group compared with the control
group (P = 0.015, P < 0.001, Figure 1C and D). Patients in
CTEPH group had significantly higher ADMA level than
the control group (P < 0.001, Figure 1E).els. Data are presented as mean ± standard deviation in Figure A, C
no significant difference in the level of d-ROMs between PAH group
e level of MDA was higher in PAH and CTEPH patients than that in
up and CTEPH-control group. C. Compared with controls, the level of
ith controls, the level of SOD was significantly lower in patients with
ntly higher in patients with PAH or CTEPH.
Table 2 The Correlation between Oxidant-antioxidant
Biomarkers and ADMA
Biomarkers PAH CTEPH
r P r P
d-ROMs -0.011 0.958 0.151 0.333
MDA -0.017 0.958 0.422 0.072
BAP -0.420 0.175 -0.333 0.164
SOD -0.436 0.156 0.346 0.147
PAH = pulmonary arterial hypertension; CTEPH = chronic thromboembolic
pulmonary hypertension; d-ROMS = derivative of reactive oxygen molecules;
MDA =malondialdehyde; BAP = biological antioxidant potential; SOD = superoxide
dismutase; ADMA= asymmetric dimethylarginine.
Table 4 The Correlation between the Biomarkers and
PVRI
Biomarkers PAH CTEPH
r P r P
d-ROMs 0.352 0.353 -0.410 0.115
MDA 0.022 0.956 0.266 0.320
BAP -0.581 0.101 -0.491 0.053
SOD -0.654 0.056 0.043 0.875
ADMA 0.603 0.038* -0.097 0.700
PVRI = pulmonary vascular resistance index; PAH = pulmonary arterial
hypertension; CTEPH = chronic thromboembolic pulmonary hypertension;
d-ROMS = derivative of reactive oxygen molecules; MDA =malondialdehyde;
BAP = biological antioxidant potential; SOD = superoxide dismutase;
ADMA = asymmetric dimethylarginine.
*The difference is statistically significant.
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We analyzed the correlation between the biomarkers
(including d-ROMs, MDA, BAP, SOD and ADMA)
and mPAP, PVRI, 6MWD, respectively, as well as the
correlations between oxidative-antioxidative biomarkers and
ADMA. The Pearson correlation coefficient and P value
were listed in Tables 2, 3, 4 and 5. No significant correlation
was found between oxidative-antioxidative biomarkers
and ADMA (Table 2). In patients with PAH, ADMA
correlated positively with mPAP (r = 0.762, P = 0.006) and
PVRI (r = 0.603, P = 0.038) (Figure 2).
Discussion
Oxidative-antioxidative status in PH
OS, an imbalance between ROS and antioxidant
molecules, has been reported to be associated with
various diseases, such as diabetes [26] and atherosclerosis
[27]. Hypoxia, hypoperfusion, and instability in pulmonary
circulation in PH may cause OS. In animal models, OS
was found to be associated with the pathogenesis and
development of PH [10]. However, few studies have
explored the application of oxidative-antioxidative bio-
markers in PH patients.
BAP and d-ROMs reflect the level of total antioxidants
and oxidants in the samples, respectively. Previous studiesTable 3 The Correlation between the Biomarkers and
mPAP
Biomarkers PAH CTEPH
r P r P
d-ROMs 0.174 0.610 -0.273 0.231
MDA -0.107 0.754 0.087 0.709
BAP -0.460 0.155 -0.132 0.569
SOD -0.341 0.305 0.118 0.611
ADMA 0.762 0.006* -0.097 0.700
mPAP =mean pulmonary arterial pressure; PAH = pulmonary arterial
hypertension; CTEPH = chronic thromboembolic pulmonary hypertension;
d-ROMS = derivative of reactive oxygen molecules; MDA =malondialdehyde;
BAP = biological antioxidant potential; SOD = superoxide dismutase;
ADMA = asymmetric dimethylarginine.
*The difference with control is statistically significant.found that d-ROMs level was high in COPD patients [28],
and was associated with the severity of IPF [20]. BAP level
was significantly lower in patients with metabolic syn-
drome [29], and was closely associated with diabetic
retinopathy and nephropathy in patients with type 2
diabetes [30].
The most possible reason for decreased BAP and SOD
level in patients with PH is the consumption of antioxi-
dant substances in the OS. The level of d-ROMs stayed
normal in PAH and CTEPH, which was possibly in
compensatory status. The finding of our study suggests
that OS contributes to the pathogenesis of PAH and
CTEPH. In animal models, SOD augmentation regresses
experimental PAH [31]. The antioxidant therapy might
be used as a supplement in the treatment of PH.
In a group of 347 patients who underwent echocardio-
graphic assessment, the relationship between pulmonary
artery systolic pressure (PASP) measured by echocardiog-
raphy and plasma aminothiol OS markers was investi-
gated. For each 1% increase in plasma cystine, PASP
increased by 16% [32]. However, in our current study, we
did not find correlation between oxidative-antioxidative
biomarkers and mPAP or PVRI measured in right heartTable 5 The Correlation between the Biomarkers and
6MWD
Biomarkers PAH CTEPH
r P r P
d-ROMs -0.357 0.386 -0.092 0.765
MDA -0.071 0.867 -0.311 0.301
BAP 0.546 0.162 -0.166 0.588
SOD 0.548 0.159 0.477 0.100
ADMA -0.454 0.259 -0.369 0.264
6MWD = 6-minute walk distance; PAH = pulmonary arterial hypertension;
CTEPH = chronic thromboembolic pulmonary hypertension; d-ROMS= derivative
of reactive oxygen molecules; MDA =malondialdehyde; BAP = biological
antioxidant potential; SOD = superoxide dismutase; ADMA = asymmetric
dimethylargininenn.
Figure 2 The correlation between ADMA and mPAP, PVRI in patients with PAH. In patients with PAH, mPAP (r = 0.762, P = 0.006) and PVRI
(r = 0.603, P = 0.038) were both positively associated with the level of ADMA.
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different OS biomarkers and different procedures to
measure pulmonary artery pressure. Another possible
reason is the limited sample size of our study. Right
heart catheterization is the golden standard for PH
diagnosis and mPAP is more accurate than PASP esti-
mated in echocardiography. The relationship between
OS biomarkers and pulmonary artery pressure needs
to be explored in more patients who undergo right
heart catheterization assessment.
Increased ADMA in PH and its significance
ADMA is a natural ubiquitous amino acid. The lungs
are a major source of NO synthase and ADMA, which
are in a dynamic balance and determine NO production
[33]. ADMA has multiple functions, such as vasoconstric-
tion, impairing endothelial-related dilatation, and increas-
ing endothelial adhesivity [34]. Plasma ADMA levels are
related with endothelial dysfunction. ADMA levels are
elevated in many cardiovascular and metabolic diseases
such as coronary artery disease [35] and hypertension
[36]. In our study, ADMA level was elevated in PH,
which is consistent with previous studies [17,18,37-39].
The potential mechanism that ADMA contributes to PH
has been studied recently. ADMA is metabolized by
dimethyl-arginine dimethylaminohydrolase. Suppression
of endothelial dimethyl-arginine dimethylaminohydrolase
expression and function represents as an important
underlying mechanism in hypoxia-induced PH [40] and
IPAH [41]. ADMA may induce pulmonary endothelial
dysfunction via changes in the expression and activity of
connexin 43 [42].Also in our current study, the serum ADMA level
correlated positively with mPAP in PAH patients, as
well as PVRI. In previous studies, plasma ADMA
concentrations correlated with mixed venous saturation,
right atrial pressure, and cardiac index [18]. These findings
indicate that the down-regulation of NO/cGMP pathway
plays a crucial role in PAH, and the inhibition degree of
this pathway affects the disease severity. The possible
explanation for this association is that the NO/cGMP
pathway regulates pulmonary vascular tone, which
can be reflected directly by mPAP and PVRI. The
pathophysiological role of ADMA in PAH still remains to
be investigated. The relationship between the ADMA and
NO system is probably more complicated than currently
known. Since ADMA correlates with multiple parameters
of pulmonary hemodynamics, it may be useful in the
evaluation of disease severity, assessment of therapeutic
efficiency, and risk stratification in patients with PAH or
other kinds of PH. Given the small sample size of our
study, further studies are needed to explore the values of
ADMA in PH.
Relationship between oxidative-antioxidative biomarkers
and ADMA
Accumulating evidences have demonstrated that NO is
closely associated with ROS. During chronic hypoxia,
increased vascular superoxide anion production adversely
impact endothelial function by impairing NO signaling
[43]. When enough ROS are produced, they will start
reacting readily with NO to form the peroxynitrite [44].
NO, the endothelium-derived relaxing factor, decreases
smooth muscle metabolism and reduces ROS production.
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retinal capillary endothelial cells [45]. In this study, we did
not find association between oxidative-antioxidative
biomarkers and ADMA in peripheral serum. The level of
these biomarkers in peripheral circulation is a reflection of
overall production and cleavage of ROS, RNS, and
NO, which is more complicated and may be affected
by various factors.
The pathogenesis of PH is a complex multifactorial
process. OS and impaired NO/sGC/cGMP signal
pathway are both involved, and their relationship is
complicated. We speculate that ROS increase first,
then NO decreases. The three major stimuli that drive the
vascular remodeling process are inflammation, shear stress
and hypoxia. All these stimuli may increase the production
of ROS, which leads to low levels of tetrahydrobiopterin
and L-arginine, the rate limiting co-factor and substrate for
endothelial NO synthase. Then endothelial NO synthase is
uncoupled, resulting in decreased NO production and
increased ROS production in turn [9]. We think that
this process happens rapidly in our body, therefore, we
couldn’t detect the change of oxidative-antioxidative bio-
markers before the change of NO signaling biomarkers
like ADMA and vice versa.
Conclusions
In summary, the antioxidative potential decreases while
serum ADMA is elevated in PAH and CTEPH patients.
Increased ADMA serum levels are associated with un-
favorable pulmonary hemodynamics in PAH patients.
ADMA may be useful in the severity evaluation and risk
stratification of PAH.
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